Conversely, a neutrophil subset that favors anti-tumor immunity has recently been identified, while neutrophils have also been required for complete tumor eradication under PD-1 and cytotoxic T lymphocyte-associated antigen 4 inhibitors treatment (43, 44). Here, CTLA4 is linked to neoplasm.